Financial Insights That Matter
By Sabrina Valle and Patricia Weiss
NEW YORK/FRANKFURT (Reuters) – Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics.
Merck, in a statement, said its negotiations to buy SpringWorks are ongoing, confirming an earlier report from Reuters. The Darmstadt, Germany-based company said that no legally binding agreement has been signed and there is no certainty a deal will materialize.
SpringWorks declined to comment.
If the talks are successful, a deal could be signed in the coming weeks, three sources told Reuters earlier in the day, requesting anonymity as the discussions are confidential. They did not disclose the exact terms being discussed.
SpringWorks’ shares closed 34% higher on Monday, giving the company a market value of around $4 billion. The stock initially jumped nearly 49% on the Reuters report, and touched its highest level since April 2022.
Merck’s German-listed shares closed down 3.7%.
Dealmaking in the U.S. healthcare sector is showing signs of picking up, after a slowdown in activity in 2024 as large pharmaceutical companies took a breather to integrate big acquisitions they completed the previous year. Johnson & Johnson last month agreed to buy Intra-Cellular Therapeutics for about $14.6 billion.
Stamford, Connecticut-based SpringWorks, which listed its shares in New York in 2019, is a commercial-stage biotech firm that develops drugs to treat various forms of cancer, including rare tumors and uterine cancer. Its monotherapy drug for the treatment of desmoid tumors, which are dense, soft-tissue tumors, has been approved in the United States. The company is expecting the approval of a product that treats neurofibromatosis type-1, a rare genetic disorder, later in February.
STRATEGIC BET
A transaction for SpringWorks would rank as one of the biggest pharma deals for Merck in recent years and boost its efforts to build out its cancer treatment pipeline.
Merck has suffered high-profile setbacks recently in late-stage drug trials, prompting it to halt development of head and neck cancer drug Xevinapant. A major trial testing multiple sclerosis drug Evobrutinib failed in December 2023.
In its most recent quarterly earnings, Merck reported a 12% rise in adjusted quarterly earnings, helped by temporarily lower spending on drug development and a rebound in demand for its specialty materials.
“Given Merck KGaA’s existing franchise in oncology, which constitutes about 25% of its healthcare sales in 2024, we see the potential acquisition of SpringWorks as likely complementary and giving potential for synergies,” analysts at JPMorgan wrote in a note.
#1a73e8;">Boost Your Financial Knowledge and Achieve Stability
Discover a growing online community dedicated to delivering financial news, tips, and strategies designed to help you manage money effectively, save smarter, and grow your investments with confidence.
#1a73e8;">Top Financial Tips for Saving and Investing
- Personal Finance Management: Master the art of budgeting, expense tracking, and building a strong financial foundation.
- Investment Opportunities: Stay updated on market trends, learn about stocks, and explore secure ways to grow your wealth.
- Expert Money-Saving Advice: Access proven techniques to reduce expenses and maximize your financial potential.